Abstract Details

Migraine is a debilitating neurological condition, affecting 15% of Americans. A long-term safety study of rimegepant showed evidence of decreased monthly migraine days (MMD) in migraineurs treated with rimegepant 75mg.

To characterize migraine-specific quality of life (MSQ v2.1) scores and mapped EQ-5D utility values in people with migraine treated with rimegepant 75mg.

Participants were randomized into two treatment regimens: individuals with 2-14 MMDs who received rimegepant 75mg as needed (PRN), and those with 4-14 MMD at baseline who received rimegepant on a fixed every-other-day schedule (QOD+PRN). MSQ, characterized by the role function-preventive (RP), role function-restrictive (RR) and emotional function (EF) domains, was mapped to EQ-5D utilities using a validated algorithm. Outcomes were assessed at baseline and week 12 (QOD+PRN) and weeks 12, 24, 36, and 52 (PRN).

At baseline, MSQ data were available for 1,892 patients: 1,078 with 2-8 MMD (PRN), 506 with 9-14 MMD (PRN), and 308 with 4-14 MMD (QOD+PRN). For all MSQ domains and mapped utility values, outcomes improved over each study visit. At baseline, EQ-5D utilities were 0.66 for the 2-8 MMD PRN group, 0.63 for the 9-14 MMD PRN group, and 0.66 for the 4-14 MMD QOD+PRN group. At end-of-study, utilities had increased by +0.09, +0.10 and +0.12 for the three groups (p<0.001, all comparisons with baseline). Similar trends in improvement were observed across MSQ subdomains, all differences were statistically significant. Greater increase in EQ-5D was observed for patients with greater reduction in MMD.

Rimegepant 75mg, is associated with reduced MMD and improvement in MSQ domains over time, leading to increased EQ-5D utilities. While improvement was observed in all patient-groups, it was most pronounced in those with higher MMD at baseline and those taking rimegepant on a QOD+PRN schedule.